Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02437370
Title Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of California, Davis
Indications

urethra transitional cell carcinoma

ureter transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

Therapies

Pembrolizumab

Gemcitabine

Docetaxel

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
University of California Davis Comprehensive Cancer Center Sacramento California 95817 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field